Neurocrine Biosciences, Inc.

SAN DIEGO, May 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. The live ... read more

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2013. For the first quarter of 2013, the Company reported net loss of $12.1 million, or $0.18 loss per share, compared to a ... read more

SAN DIEGO, April 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2013 financial results after the Nasdaq market closes on Thursday, May 2, 2013. Neurocrine will then host a live conference call ... read more

SAN DIEGO, April 24, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Needham 12(th) Annual Healthcare Conference in New York City. The live presentation takes place ... read more

SAN DIEGO, March 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, in development by AbbVie for the treatment ... read more

SAN DIEGO, March 11, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 25(th) Annual Roth Conference in Laguna Niguel. The live presentation takes place on Monday, March 18 ... read more

SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 33(rd) Annual Health Care Conference in Boston. The live presentation takes place on ... read more

SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2012. For the fourth quarter of 2012, the Company reported net income of $9.5 million, or $0.14 per fully diluted share, ... read more

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Leerink Swann Global Healthcare Conference 2013 in New York City. The live presentation takes place on ... read more

SAN DIEGO, Feb. 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2012 financial results before the Nasdaq market opens on Friday, February 8, 2013. Neurocrine will then host a live ... read more

SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2) NBI-98854. European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office ... read more

SAN DIEGO, Dec. 18, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect 2 Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this six-week Phase IIb study is a randomized, ... read more

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 2012 dbAccess BioFEST in Boston. The live presentation takes place on Tuesday, December 4 at ... read more

SAN DIEGO, Nov. 20, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 24(th) Annual Piper Jaffray Healthcare Conference in New York. The live presentation takes place on Tuesday, November ... read more